Hypertension and survival in chronic hemodialysis patients—Past lessons and future opportunities  by Agarwal, Rajiv
Kidney International, Vol. 67 (2005), pp. 1–13
PERSPECTIVES IN RENAL MEDICINE
Hypertension and survival in chronic hemodialysis
patients—Past lessons and future opportunities
RAJIV AGARWAL
Indiana University School of Medicine, Indianapolis, Indiana
Hypertension and survival in chronic hemodialysis patients—
Past lessons and future opportunities. There is substantial con-
troversy surrounding the benefits of control of hypertension
in hemodialysis patients. Unlike the general population, some
studies suggest that higher blood pressure in hemodialysis pa-
tients offers a survival advantage, what is termed as “reverse
epidemiology.” To critically analyze the relationship between
total and cardiovascular mortality and blood pressure, peer-
reviewed, published studies in hemodialysis patients were an-
alyzed. Consideration of the world-wide experience suggests
that analysis of incident cohorts reveal a clear link between el-
evated blood pressure and mortality. Increased pulse pressure,
which is primarily due to increased systolic pressure, is also as-
sociated with cardiovascular morbidity and mortality. The coun-
terintuitive relationship between blood pressure and mortality
appears, in part, to be due to methods of data analysis. When
data are analyzed with systolic or diastolic blood pressure as
separate models, not conjointly, inverse relationship between
blood pressure and total and cardiovascular mortality is gen-
erally seen. When both systolic and diastolic blood pressure
are considered together, systolic blood pressure or increased
pulse pressure assumes a major importance in predicting car-
diovascular events whereas diastolic blood pressure retains the
inverse relationship. Control of hypertension in hypertensive
dialysis patients is associated with improved survival. Further-
more, the use of antihypertensive drug treatment is associated
with improved survival regardless of blood pressure control.
Low predialysis blood pressure is associated with increased car-
diovascular deaths and deaths within 2 years from malignancy
or withdrawal from dialysis. These data suggest that hyperten-
sion needs to be better controlled in hypertensive hemodialysis
patients. Better methods of assessment of blood pressure con-
trol, consideration of cardiac structure and function, and per-
formance of randomized controlled trials of pharmacologic and
nonpharmacologic strategies are needed to establish benefits
and determining goal blood pressure in hemodialysis patients.
In the early days of dialysis, hypertension requiring
pharmacologic therapy was seen only in 10% to 15%
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of the patients perhaps due to dialysate and dietary
sodium restriction, attention to dry-weight and long-hour
hemodialysis [1]. However, more recent data suggest that
the prevalence of hypertension in patients on chronic
hemodialysis exceeds that seen in the general population
[2] or those with chronic kidney disease (CKD) [3]. Us-
ing various definitions of hypertension, the prevalence of
hypertension in hemodialyis patients is estimated to be
about 75% [4, 5]. Unlike the early days of dialysis, anti-
hypertensive therapy is now widely used to control blood
pressure and its use varies from 59% to 83% [4–7].
In a more recent study, the prevalence, treatment, and
control of hypertension, defined as an average predial-
ysis systolic blood pressure >150 mm Hg or diastolic
blood pressure >85 mm Hg, or the use of antihyper-
tensive medications was investigated in a cohort of 2535
clinically stable, adult hemodialysis patients [8]. Hyper-
tension was present in 86% of patients. The prevalence of
hypertension, in contrast to that observed in the general
population, did not increase linearly with age and was
not affected by gender or race. Hypertension was con-
trolled adequately in only 30% of the hypertensive pa-
tients. In the remaining patients, hypertension was either
untreated (12%) or was poorly controlled (58%). Thus
the control of hypertension, particularly systolic hyper-
tension, in chronic hemodialysis patients in the United
States is inadequate, despite recognition of its prevalence
and the frequent use of antihypertensive drugs.
Despite this high prevalence and pharmacologic treat-
ment rates in hypertensive hemodialysis patients, recent
data have questioned the link between hypertension and
survival in chronic hemodialysis patients [9–12]. These
studies, which suggest a paradoxic relationship between
higher predialysis systolic blood pressure and a lower di-
astolic blood pressure with improved survival, call into
question the wisdom of adequate blood pressure control
in patients on chronic hemodialysis.
The purpose of the present review is to examine stud-
ies that analyze hypertension as a risk factor for total and
cardiovascular mortality in patients on chronic hemodial-
ysis. By examining the study design, duration of follow-
up, use of antihypertensive drugs, and other biologically
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important covariates, I have attempted to reconcile the
differences between the studies to answer the question.
Should hypertension be controlled, what are the deficien-
cies in our analysis of current cohort studies and what
can future studies learn from the collective data that now
exists?
No adequately powered randomized controlled trials
have been reported to ascertain target blood pressure or
the agent used in patients on chronic hemodialysis. Ob-
servational cohort studies have reported the relationship
of hypertension and cardiovascular and total mortality.
These studies either use patients who are new to dialysis
or incident patients; therefore, these studies are those
of incident cohorts. Studies that use existing patients
on hemodialysis and follow them over a period of time
are prevalent cohort studies. There are important differ-
ences in the outcomes of these studies and therefore they
are discussed separately. Demographic and clinical char-
acteristics of the study populations are summarized in
Table 1.
STUDIES WITH INCIDENT COHORTS
Silverberg et al [13] compared highest (>166 g/m2) and
lowest quintiles (<83 g/m2) of echocardiographic left ven-
tricular mass index and mortality. Unadjusted total and
cardiac mortality was 3.7 times higher in the highest quin-
tile that was reduced to 2.9 for total mortality and to 2.7
for cardiac mortality, but remained significant after ad-
justment for age, hypertension, and angina, diabetes, and
transplantation. Left ventricular cavity dilatation at end
systole was associated with 3.2 higher risk of total mortal-
ity. Hypertension did not emerge as a significant predictor
of total mortality or cardiac mortality. However, the small
sample size, relatively short follow-up, and correlation
of hypertension with left ventricular mass make it diffi-
cult to assess the risk of hypertension as an independent
risk factor. Although the relative contributions of hyper-
tension and other factors such as valvular heart disease,
anemia, hyperparathyroidism, and arteriovenous fistula
on left ventricular mass assessment are poorly defined in
the dialysis population, increase in left ventricular mass is
well correlated with hypertension. Accordingly, left ven-
tricular mass index, which is a more accurate reflection
of the burden of hypertension, was associated with to-
tal and cardiovascular mortality suggesting that routine
blood pressure measurements may not accurately assess
the burden of hypertension in hemodialysis patients.
Foley et al [14] performed echocardiograms to assess
left ventricular mass and function within 3 months after
the start of dialysis. De novo and recurrent cardiac failure
and ischemic heart disease were recorded during follow-
up and adjusted for hemoglobin, mean arterial blood
pressure, and serum albumin levels as averaged monthly
values from the beginning of dialysis therapy to the de-
velopment of the event in question. The impact of mean
blood pressure was adjusted for age, diabetes mellitus, is-
chemic heart disease, serum albumin, and hemoglobin
level. Patients with the lowest tertile of mean arterial
blood pressure of 98 mm Hg or less had more adverse
prognostic features at baseline, such as older age hypoal-
buminemia, ischemic heart disease, and heart failure. In
hemodialysis patients each 10 mm Hg rise in mean arterial
pressure level was associated with a 7.2 g/m2 increase in
left ventricular mass index on repeat echocardiography
and an increased likelihood of developing first episode
of cardiac failure [risk ratio (RR) 2.07] (P = 0.004). An
inverse relationship between blood pressure and mortal-
ity was observed (RR 1.37 for 10 mm Hg fall in mean
arterial pressure). After adjusting for adverse cardiovas-
cular risk factors, hypertension was found to be a strong
predictor of echocardiographic left ventricular hypertro-
phy (LVH) and de novo cardiac failure. Concentric LVH
and left ventricular dilatation were more commonly seen
among hypertensive end-stage renal disease (ESRD)
patients. De novo cardiac failure and ischemic heart dis-
ease was also more common among hypertensive indi-
viduals. This study showed a strong association between
low blood pressure and adverse cardiovascular risk fac-
tors. The risk of death was increased among patients with
hypotension. Cardiac failure was by far the predominant
condition leading to death. Following the onset of cardiac
failure, the major predictor of death was a lower blood
pressure. The data suggest that the inverse relationship
between blood pressure and mortality reflect the fact that
the cardiac failure or other events leading to hypotension
had occurred prior to death.
Two Japanese reports [15, 16] reported by the same
group of investigators appear to be the same cohort of
patients from Osaka, Japan. No patients were excluded
from the analysis and the use of antihypertensives was
not reported. There were 66 deaths reported, of which
26% were cardiovascular. Crude mortality was 24% at
3 years, 31% after 5 years, and 46% at 10 years—much
lower than what is currently seen in the United States.
Prior to dialysis, blood pressures were lower in the sur-
vivors (167 mm Hg systolic) compared to nonsurvivors
(178 mm Hg systolic). Similarly, during the maintenance
phase, blood pressure in the survivors (147 mm Hg sys-
tolic) was lower than the nonsurvivors (165 mm Hg sys-
tolic). Importantly, in patients who had a systolic blood
pressure of > 160 mm Hg at baseline and in whom sys-
tolic blood pressure during the maintenance phase was
lowered to 160 mm Hg or less had a better survival than in
patients who continued to be hypertensive during the
maintenance phase. Diastolic blood pressures between
the two groups were similar. The relationship of blood
pressure and mortality was modified by the presence
or absence of ischemic heart disease. Thus, if ischemic
heart disease was present, higher blood pressure was
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protective. However, in those patients with systolic hy-
pertension, survival was worse when the total cholesterol
was 220 mg/dL or more, or when the subjects smoked.
This report points out the need for prolonged follow-up,
and consideration of comorbidities such as underly-
ing cardiovascular disease, when dissecting the rela-
tionship between hypertension and mortality in dialysis
patients. Furthermore, the study points out that lowering
blood pressure to normotensive levels in dialysis patients
who were relatively healthy is associated with improved
survival.
Lynn et al [17] reported a retrospective incident co-
hort study, of home hemodialysis and peritoneal dialy-
sis patients from New Zealand. A cubic spline function
was computed for blood pressure to accommodate the
curvilinear relationship between blood pressure and to-
tal mortality. Blood pressure before the first dialysis was
147.3 ± 20.5/81.5 ± 14.1 mm Hg and was used to predict
risk. Whereas 76% of the patients had taken antihyper-
tensive drugs for 6.7 years, only 4.7% continued on these
drugs while on dialysis. Univariate analysis showed that
the baseline covariates that predicted all-cause mortality
were age, mean blood pressure, serum albumin, diabetes,
peripheral, coronary, or cerebrovascular disease, chronic
lung disease, current or previous smoking, body mass
index, and treatment modality. In the joint Cox model,
only five of these predictors remained significant—age,
serum albumin, diabetes, peripheral vascular disease, and
chronic lung disease besides mean blood pressure. Aver-
age blood pressure at start of dialysis predicted survival
on its own (P = 0.0009) and in the adjusted model (P =
0.047). In the cubic spline model, both high and low mean
blood pressure values of the start of dialysis were associ-
ated with the highest mortality, the optimum mean blood
pressure was about 100 mm Hg. The mean blood pres-
sure at 1 year, indicative of residual hypertension treated
with dialysis, was examined as a predictor of subsequent
survival. Residual hypertension continued to be associ-
ated with death (median survival 4.05 years for medium
blood pressure vs. 1.82 years for high blood pressure, P =
0.03) and there was no survival disadvantage afforded by
low mean pressure. The study points out that lower blood
pressure in dialysis patients who were relatively healthy
was associated with improved survival.
Lucas et al [18] reported a retrospective incident co-
hort study of nondiabetic patients from Madrid, Spain.
Crude mortality rates were 79/1000 patient years for
normotensive, 87/1000 patient years for controlled hy-
pertensive and 141/1000 patient years for uncontrolled
hypertensive patients. After adjusting for age, gender,
serum albumin level, vascular calcifications, history of hy-
pertension, and cardiovascular comorbidity in the Cox
proportional hazards model the relative risk of uncon-
trolled hypertension was 2.93 (95% CI 1.68 to 5.12,
P <.0001) for cardiovascular mortality and the relative
risk of uncontrolled hypertension was 1.79 (95% CI 1.15
to 2.8, P = .01) for total mortality. In patients who were
normotensive prior to dialysis, uncontrolled hyperten-
sion was seen only in 4% after onset of dialysis, in those
with controlled hypertension 9% were uncontrolled,
whereas in those patients with uncontrolled hyperten-
sion prior to dialysis 30% remained uncontrolled follow-
ing institution of dialysis therapy. These data suggest that
uncontrolled hypertension in pre-ESRD patients is an
important predictor for cardiovascular mortality during
ESRD. Although it is clear that treatment of hyperten-
sion must start before the patient reaches dialysis, it is less
clear from these data if control of hypertension once the
patient has reached dialysis can reduce cardiovascular
morbidity and mortality. Nevertheless, the study points
out that lower blood pressure in dialysis patients who
were relatively healthy was associated with improved
survival.
Two reports [19, 20] from the same group of investi-
gators in Tassin, France, have reported the influence of
mean arterial pressure on survival in hemodialysis pa-
tients. In the first report [19], 20-year survival on 445 pa-
tients who received 8 hours of dialysis three times a week
was reported. Six months after starting dialysis 98% of
the patients were normotensive and off blood pressure
medications. Only seven patients (1.6% of the total pop-
ulation) were receiving antihypertensive drugs. The mean
arterial pressure was split at the median to a low arterial
pressure group (average 90 mm Hg) and high mean arte-
rial pressure group (average 109 mm Hg). Higher mean
arterial pressure was associated with older age, male gen-
der, lower Kt/V, diabetes, systemic diseases, atherosclero-
sis, and malignant diseases as etiology of CKD. Mortality
rates at 5, 10, 15, and 20 years were 13%, 25%, 45%,
and 57%, respectively. With 3690 patient year follow-up,
the crude mortality rate was 24.02/1000 patient years in
those with mean arterial pressure of < 99 mm Hg and
48.61/1000 patient years in those with mean arterial pres-
sure of 99 mm Hg or more. Cardiovascular death rate was
9.7/1000 patient years in the low arterial pressure group
and 17.71/1000 patient years in the high mean arterial
pressure group. These differences in total and cardiovas-
cular mortality were significant but were not adjusted for
baseline differences in risk factors. Thus, the independent
effect of blood pressure on total and cardiovascular mor-
tality is not clear from this study.
The same group of French investigators [20] reported
on 692 patients in which the use of antihypertensive drugs
was reduced to 2.1% over 3 months. Normal mean arte-
rial pressure defined as 110 mm Hg or less was achieved in
3 months with a mean weight reduction to 2.5 kg. In 90 pa-
tients who were dialyzed elsewhere for at least 6 months
but for <5 hours per treatment, the use of antihyper-
tensive drugs dropped from 46% to 1% after 3 months.
Mean survival was 15.3 years with a crude mortality rate
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of 45/1000 patient years. Cardiovascular mortality was
10.1/1000 patient years in the low mean arterial group
vs. 19.6/1000 patient years in the higher mean arterial
pressure group. There was 2.1% increase in risk of car-
diovascular mortality with each mm Hg increase in mean
arterial pressure. A group of 326 patients had no dia-
betes, were younger than 60 years, and did not have prior
cardiovascular disease were defined as a low-risk group.
Cardiovascular morbidity analyzed in those patients with
a low baseline risk was dependent on mean arterial pres-
sure, duration of predialysis hypertension, as well as age,
hematocrit, and triglycerides. All analyses were adjusted
for diabetes, gender, smoking, prior atherosclerotic dis-
ease, age at start of dialysis, and Babb’s dialysis index,
serum albumin, and Kt/V.
These cohort studies from Tassin, France, clearly show
the independent association of hypertension on cardio-
vascular morbidity and mortality. These studies also
support the importance of considering baseline risk in
evaluating hypertension as a risk factor for cardiovascu-
lar disease. Importantly, mean arterial pressure emerged
as a cardiovascular risk factor in those with low base-
line risk. These patients, however, were receiving long-
duration hemodialysis and it is not clear whether these
data can be extrapolated to patients who receive shorter
duration, three times a week dialyses.
Koch et al [21] have reported incident cohort of 196
German diabetic hemodialysis patients admitted to 28
dialysis units between January 1987 and October 1987
followed for an average of 57 months. Duration of hyper-
tension, LVH by electrocardiogram or echocardiogram,
blood pressure at time of admission to dialysis unit or av-
erage predialysis blood pressure were not predictive of
total or cardiovascular mortality.
London et al [22], in the only interventional study in
the literature, reported 153 hemodialysis patients treated
with dry-weight reduction, antihypertensive treatment,
and correction of anemia on regression of LVH. In this
study, over 54 months, blood pressure reduced from
169/90 mm Hg to 147/78 mm Hg; hemoglobin increased
from 8.65 to 10.5 g/dL and left ventricular mass reduced
from 290 ± 80 g to 264 ± 86 g (P < 0.01). The hazard ratio
(HR) for total mortality was 0.78 and cardiovascular mor-
tality 0.72 with 10% reduction in left ventricular mass, in-
directly implicating hypertension control with outcomes
in hemodialysis patients.
Taken together, the incident cohorts and an interven-
tional study suggest that hypertension is a risk factor
for the development and progression of LVH, cardiovas-
cular and total mortality. In populations with relatively
little morbidity, hypertension manifests itself as a risk
factor. Furthermore, if normotension is achieved in the
hypertensive cohort and patients are followed for an ad-
equate duration, normotensive in contrast to hyperten-
sive patients have a better survival. LVH, which is in part
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Fig. 1. In incident cohorts, achieving a normal blood pressure (NT)
with dialysis in hypertensive patients (HT) is associated with im-
proved survival. Those who remain hypertensive have the worst survival
(adapted from Tomita J et al, Am J Kidney Dis 25:405–412, 1995).
dependent upon the total blood pressure burden on the
cardiovascular system, is an important surrogate for pre-
dicting cardiovascular and total mortality.
STUDIES WITH PREVALENT COHORTS
Several prevalent cohort studies have been reported
that have the association of hypertension with cardiovas-
cular and total mortality in chronic hemodialysis patients.
These studies are briefly reviewed according to the geo-
graphic origins of the cohorts and clinical characteristics
are reported in Table 1.
Japanese cohorts
A prevalent cohort of patients has been reported from
Okinawa, Japan, initially in 1997 [11] and subsequently in
2002 [23]. For analyzing risk, blood pressure of 130/80 mm
Hg was designated as the reference standard. Blood pres-
sure was treated as a continuous variable in the Cox
proportion hazards model where single blood pressures,
systolic, and diastolic, or pulse pressures were considered.
Also conjoint models were developed where simultane-
ous effects of systolic and diastolic, systolic and pulse
pressure, and diastolic and pulse pressure will considered
jointly. A total of 38% of the cohort died over 7877 patient
year follow-up. The crude mortality rate was 60.3/1000 pa-
tient years, stroke rate 14.4/1000 patient years, and acute
myocardial infarction 3.2/1000 patient years. In the single
blood pressure component model, pulse pressure was the
strongest predictor of fatal outcome (HR 1.080 per 10 mm
Hg increase in pulse pressure). The systolic blood pres-
sure was also significant predictor (HR 1.040 per 10 mm
Hg increase) but not as strong as pulse pressure. Diastolic
blood pressure was not significant predictor of total mor-
tality. When both the systolic and diastolic blood pres-
sures were considered together, systolic blood pressure
was associated with increased total mortality (HR 1.083)
but diastolic blood pressure was associated with reduced
total mortality (HR 0.886) (Fig. 2). When considered to-
gether systolic blood pressure (HR 1.116) was associated
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Fig. 2. Systolic and diastolic blood pressures
have opposite influence on cardiovascular
events and total mortality. Consideration of
both blood pressures in a conjoint model
would allow for adjusting for diastolic blood
pressure when systolic blood pressure is high,
uncovering the role of hypertension in causing
cardiovascular events (adapted from Tozawa
M et al, Kidney Int 61:717–726, 2002).
with increased risk of cardiovascular events but not dias-
tolic blood pressure. These observations on a large cohort
of patients, with relatively low crude mortality rate, fol-
lowed for cardiovascular events and total mortality point
out the need to consider the influence of systolic and di-
astolic blood pressure together when assessing the risk
of hypertension on cardiovascular morbidity and mortal-
ity in hemodialysis patients. When patients with diabetes,
who have an increased mortality rate, were considered
separately, no effect of blood pressure as a risk factor
was obvious.
In a case-control study, Kawamura et al [24] compared
blood pressure in 35 patients on hemodialysis who devel-
oped cerebral hemorrhage with 66 controls on hemodial-
ysis matched for age, gender, etiology of renal disease,
age at initiation of hemodialysis, and duration of dialysis.
Predialysis blood pressure in the 3 to 4 months preceding
the hemorrhage were higher in cases compared to con-
trols (prehemodialysis blood pressure 171/89 mm Hg in
cases, compared to 154/81 mm Hg in controls, P < 0.001)
suggesting a role of uncontrolled hypertension in the eti-
ology of cerebral hemorrhage.
South American cohorts
Two cohorts [25, 26] from Montevideo, Uruguay, have
been reported by the same group of investigators. In the
first cohort, Fernandez et al [25] found that predialysis
mean arterial pressure of >115 mm Hg was associated
with death or hospitalization. Although poor cardiac sta-
tus, older age, and low hemodialysis dose were also pre-
dictive or mortality and morbidity, mean arterial pressure
was the most important treatment-related mortality and
morbidity factor.
In a second investigation from the same group,
Mazzuchi, Carbonell, and Fernandez-Cean [26], reported
405 patients who had been on dialysis for at least 2 years.
Total mortality was reported as early mortality <2 years
and late mortality >2 years. There were 65 deaths in the
first 2 years and 69 late deaths. With cumulative 1390 pa-
tient year follow-up, crude mortality rate was 96.4/1000
patient years. Crude mortality rate at 1 year was 9.4%, at
2 years was 24.2%, and at 3 years was 28.7%. Whereas
early mortality was associated with diastolic blood pres-
sure of <75 mm Hg (HR = 2.52, P = 0.0042) of which 34%
were cardiovascular deaths, late mortality was associated
with systolic blood pressure >160 mm Hg (HR 2.19, P =
0.047) of which 46% were cardiovascular deaths. The au-
thors of this study suggest that early mortality associated
with low diastolic blood pressure may be attributable to
disease processes that lower the diastolic blood pressure.
Late mortality, on the other hand, may be attributable to
cardiovascular effects of systolic hypertension.
De Lima et al [27] have reported a healthier preva-
lent cohort from Brazil. Patients younger than 20 years
at initiation of dialysis, who had been on dialysis for less
than 8 months and had evidence of for cardiovascular dis-
ease, defined as heart failure, myocardial infarction, cere-
brovascular accident, and vasculopathy, were excluded.
Over 6 1/2 years of follow up, 44 patients died—46% of
these were cardiovascular deaths. Overall, survival was
93%, 64%, and 30% at 1, 5, and 12 years, respectively.
Sudden death, cerebrovascular accident, and infections
were the most common causes of death. The relative risk
of total mortality in those with hypertension was 2.04 (P =
0.019) and in multivariate analysis, after adjusting for con-
founding variables, hypertension was associated with the
RR of 2.22 (P = 0.026) for the risk of total mortality.
In summary, younger patients with low baseline mor-
tality have relatively large risk of total or cardiovascu-
lar mortality associated with hypertension. Early deaths
associated with low diastolic blood pressure may be at-
tributable to disease processes that lower the diastolic
blood pressure.
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European cohorts
Degoulet et al [28] analyzed demographic and labo-
ratory factors associated with mortality from 33 French
dialysis units. Over 2063 patient-years of follow-up, 198
deaths, 111 noncardiovascular deaths, 87 cardiovascular
deaths, including 35 strokes and 22 myocardial infarc-
tions, were seen. Crude mortality rate was 96/1000 pa-
tient years and the cumulative survival rate was 89.6%
at 1 year, 81.6% at 2 years, 77.7% at 3 years, and 74.3%
at 5 years. After adjusting for age and gender, those in
the highest tertile of systolic blood pressure (155 mm
Hg or more) had observed to expected total mortality
of 1.33, cardiovascular mortality of 1.46 and standard-
ized mortality of 1.90. For the highest tertile of diastolic
blood pressure (89 mm Hg or more) observed to ex-
pected total mortality was 1.27, cardiovascular mortality
was 1.57, and stroke mortality was 1.87. All differences
noted above were statistically significant. Observed to
expected cardiovascular mortality was 0.86 in the lowest
tertile (<138 mm Hg), 0.68 in the middle tertile, and 1.46
in the highest tertile, suggesting a U-shaped relationship.
Of the 35 fatal strokes, only three occurred in lowest ter-
tile of diastolic blood pressure (<78 mm Hg), whereas 21
were observed in the highest tertile.
Duranti, Imperiali, and Sasdelli [12] reported an Ital-
ian cohort of 370 prevalent hemodialysis patients who had
been on chronic hemodialysis for 5.9 years. A total of 46%
of the patients died over 2183 patient years of follow-up,
yielding a crude mortality rate of 77/1000 patient years.
No effect of hypertension was observed on total mor-
tality. However, in the younger age group, <50 years of
age, hypertension was associated with 31% mortality and
normotension with 18% mortality. This study is consis-
tent with the Japanese experience that older people on
dialysis have risk factors that influence mortality that are
stronger than hypertension.
Blacher et al [29] reported 241 patients from Paris,
France, on chronic hemodialysis of which 48% of the pa-
tients were treated with antihypertensive drugs. There
were 73 deaths, which included 48 cardiovascular deaths
and 25 noncardiovascular deaths. The Cox proportional
hazards model was adjusted for pulse wave velocity (a
marker of vascular stiffness), hemoglobin, age, and time
on dialysis before inclusion. In the adjusted model di-
astolic blood pressure was inversely related to all-cause
mortality (r = −0.020, P = 0.05) and cardiovascular mor-
tality (r = −0.021, P = 0.02). Compared to individuals
with diastolic blood pressure <78 mm Hg, those with
blood pressure 78 to 94 mm Hg had the relative risk of
0.5 (95% CI 0.21 to 1.3) and those with blood pressure
of more than 94 mm Hg had the relative risk of 0.6 (95%
CI 0.3 to 1.0) of death. Pulse wave velocity emerged as a
significant predictor of all-cause and cardiovascular mor-
tality in the adjusted model. A significant relationship
was seen between systolic blood pressure and pulse wave
velocity. The study points out the important mechanis-
tic relationship between vascular wall stiffness and total
and cardiovascular mortality in hemodialysis patients. It
is likely that if systolic and diastolic blood pressures were
considered in a conjoint model the opposing effects of
systolic and diastolic blood pressures may have emerged
[23].
The same group of investigators from Paris reported a
cohort of 180 patients on chronic hemodialysis between
January 1990 and March 2000 [30]. At entry patients un-
derwent carotid pulse pressure measurements through
pulse wave analysis, echocardiography, and aortic pulse
wave velocity measurements. After adjustment for age,
time on dialysis, previous cardiovascular events, three
factors that were predictive of all cause mortality were
carotid pulse pressure, brachial/carotid pulse pressure,
and aortic pulse wave velocity. Adjusted HRs for 1 SD
increments were 1.4 for carotid pulse pressure, 0.5 for
brachial/carotid pulse pressure, and 1.3 for pulse wave ve-
locity. Brachial blood pressure, including pulse pressure,
had no predictive value for mortality after adjustments.
Since aortic blood pressure is a more important determi-
nant of cardiac and carotid artery perfusion, these results
are biologically plausible and strengthen the association
of vascular stiffness and all-cause mortality.
In the only study utilizing interdialytic ambulatory
blood pressure monitoring, Amar et al [31] from
Toulouse, France, reported 57 treated hypertensive
hemodialysis patients of which 10 died of cardiovascu-
lar causes. Although this study had a small number of
patients with a relatively short follow-up it demonstrated
that nocturnal systolic blood pressure (RR 1.41 95% CI
1.08 to 1.84) and 24-hour pulse pressure (RR 1.85, 95%
CI 1.28 to 2.65) were independent predictors of cardio-
vascular mortality in treated hypertensive hemodialysis
patients.
United States cohorts
Salem and Bower [32] reported the association of hy-
pertension with 1-year mortality in 649 hemodialysis pa-
tients. There were 71 deaths, yielding a crude mortality
rate was at least 10.9% but one that cannot be accurately
calculated due to incomplete data. In unadjusted anal-
ysis hypertension was associated with improved 1-year
survival compared to normotensive patients (HR = 0.48,
P = 0.002). Treated hypertensive patients (59% of the
population) had better survival than the normotensive
patients (HR = 0.41, P = 0.0006). When the analyses were
adjusted for age, albumin, diabetes, and antihypertensive
treatment, the effect of blood pressure before dialysis
failed to achieve significance. Nevertheless, antihyper-
tensive treatment was associated with improved survival
(HR = 0.55, P = 0.02). The survival advantage of hyper-
tension was limited to black patients. Total mortality risk
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in white patients with hypertension was 3.38 times that
seen in normotensive patients but did not reach statisti-
cal significance. Although the study was underpowered,
it raised the provocative question that antihypertensive
therapy can improve survival independent of blood pres-
sure control.
At 2-year follow-up [33] 57 of 191 normotensive sub-
jects (30%) and 100/458 hypertensive participants (22%)
had died. In univariate analysis, hypertension was asso-
ciated with improved 2-year survival compared to the
normotensive patients (HR = 0.64, P = 0.008). In an ad-
justed analysis, hypertension was no longer a protective
factor.
Zager et al [9] reported a cohort of 5433 patients from
a large dialysis chain in United States of which 42% of
the patients died over 2.6 year mean and aggregate of
14,126 patient year follow-up, yielding a crude annual
mortality rate of 16.1%. Blood pressure showed a “U”-
shaped curve with mortality. Posthemodialysis systolic
blood pressure of 180 mm Hg or more was associated
with 96% higher mortality and diastolic blood pressure of
90 mm Hg or higher was associated with 76% greater car-
diovascular mortality. On the other hand systolic blood
pressure of <110 mm Hg predialysis or postdialysis was
associated with increased cardiovascular mortality. Anti-
hypertensive therapy use was associated with 28% age-
adjusted relative mortality. These analyses were adjusted
for age, gender, ethnicity, etiology of ESRD, Kt/V, albu-
min, antihypertensive medication, duration on dialysis,
hematocrit, erythropoietin dose, and interdialytic weight
gain. Blood pressure was analyzed as both a fixed and
a time-varying covariate in a Cox proportional hazards
regression model. Time-varying covariates allow for ad-
justment of risk exposure such as blood pressure. The
effects of low blood pressure were magnified when used
as a time-varying covariate. For example, total mortal-
ity for prehemodialysis blood pressure of <110 mm Hg
was 64% higher when treated as a fixed covariate but in-
creased to 207% when treated as time-varying covariate.
When using blood pressure as a time-varying covariate, it
is possible that a risk factor other than hypertension may
simultaneously influence blood pressure and mortality—
in the latter situation, fall in blood pressure and cardio-
vascular mortality may be strongly associated, but this
does not prove causation. For example, if a hypertensive
patient who developed heart failure experienced a drop
in blood pressure, the effect of hypertension when en-
tered as a time-varying covariate would be diluted.
Two studies have been reported from the United States
Renal Data System that have analyzed the relationship
between hypertension and mortality. The first study re-
ported by Port et al [10] was a cohort analysis of 4499
patients who had been on dialysis for at least 1 year
on the last day of 1990. The proportion of patients on
antihypertensive drugs was not reported. The reference
group for systolic blood pressure was 120 to 149 mm Hg
and for diastolic blood pressure was 70 to 89 mm Hg.
Deaths due to coronary artery disease, cardiovascular
disease or “other cardiac diseases” were analyzed. All
other deaths were censored. Three models were used to
assess the independent effect of blood pressure on mor-
tality. The main model adjusted for age, albumin, body
mass index, smoking status, duration of ESRD, insulin
therapy, peripheral vascular disease, chronic obstructive
pulmonary disease, neoplasm, an inability to ambulate
or transfer. This model was also fitted for four groups of
patients vis-a´-vis those with congestive heart failure only,
those with coronary artery disease only, those with both,
and those with neither. HR for cardiovascular mortal-
ity for the main model was 1.86 for predialysis systolic
blood pressure of <110 mm Hg and 1.28 for postdialysis
systolic blood pressure of <110 mm Hg. HRs for car-
diovascular mortality was 1.32 for postdialysis systolic
blood pressure of ≥180 mm Hg and was of marginal
statistical significance (P = 0.06). Diastolic blood pres-
sure was not predictive of cardiovascular deaths except
for postdialysis diastolic blood pressure of ≥110 mm Hg
(HR = 2.25, P = 0.04). Predialysis systolic blood pres-
sure of <110 mm Hg increased the risk of cardiovascu-
lar mortality two fold, when congestive heart failure was
present with or without coronary artery disease. Coro-
nary artery disease deaths, other cardiac deaths, and non-
cardiac deaths all were increased with low predialysis
systolic blood pressure (<110 mm Hg). However, total
mortality did not reach statistical significance with low
predialysis systolic blood pressure. The “U”-shaped re-
lationship was seen with postdialysis systolic blood pres-
sure and “other deaths.” Of note, there were a large num-
ber of patients who had underlying coronary disease and
heart failure in this cohort. The number of patients who
were at lower-risk and followed for a substantial time
to uncover an effect of hypertension on cardiovascular
mortality were limited. Thus, the lack of relationship be-
tween hypertension and cardiovascular mortality was not
surprising.
The second report of Foley, Herzog, and Collins [34]
from the United States Renal Data System, used a larger
number of patients with a longer follow-up and reported
antihypertensive drug use. The techniques of data anal-
ysis were also different from the earlier report. 50.4%
of the patients were on antihypertensive drugs. Cal-
cium channel blockers were used by 35%, angiotensin-
converting enzyme (ACE) inhibitors by 14%, and beta
blockers by 8.5%. Over average follow-up of 3.8 years,
63% of the patients died yielding a median survival of
3.9 years. Thus, the crude mortality rate of 166/1000 pa-
tient years was similar to the United States hemodialy-
sis population. The authors assessed the value of systolic
and diastolic blood pressure separately and conjointly in
a Cox proportional hazards model. As expected, when
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systolic and diastolic blood pressures were considered
separately, there was an inverse relationship seen be-
tween total mortality and blood pressure. However, when
systolic and diastolic blood pressures were considered
together, a direct relationship between total mortality
and systolic blood pressure, but an inverse relationship
between diastolic blood pressure and total mortality
emerged. The HRs for total mortality were 1.06/0.79 for
predialysis blood pressures and 3.0/0.87 per 10 mm Hg
blood pressure for postdialysis blood pressures. When
the results were adjusted for important confounding vari-
ables, the HRs were 0.99/0.95 for predialysis and 1.03/0.94
for posthemodialysis blood pressures. However, all HRs
except the prehemodialysis systolic blood pressures re-
mained statistically significant. Since the analyses were
adjusted for interdialytic weight gain a higher postdial-
ysis blood pressure when adjusted for the interdialytic
weight gain may reflect inadequate achievement of dry
weight. These data suggest that inadequate attention to
dry weight or the presence of a stiff arterial circulation
may be independently associated with total mortality in
hemodialysis patients.
In the largest study reported to date, Klassen et al [35]
analyzed the relationship between blood pressure and
total mortality in 37,099 patients from a large dialysis
chain. The interaction between pulse pressure and age,
gender, race, diabetes and level of systolic blood pressure
was tested. For any given level of systolic blood pressure,
a direct relationship emerged between increasing pulse
pressure and death. Each 10 mm Hg increase in pulse
pressure was associated with 12% increase in hazards of
death. Subjects with prehemodialysis systolic blood pres-
sure of <135 mm Hg had greater mortality. Pulse pres-
sure in unadjusted analyses had a U-shaped relationship
with mortality with the reference pulse pressure of 50
to 59 mm Hg. After controlling for the level of systolic
blood pressure there was a direct relationship between
pulse pressure of ≥60 mm Hg and total mortality. Pulse
pressure was predominantly governed by systolic blood
pressure (r2 = 0.73, diastolic blood pressure r2 = 0.057).
In further the analysis, the authors demonstrated that the
pulse pressure related mortality was driven by those with
systolic blood pressure <140 mm Hg. There was an im-
portant interaction between pulse pressure and age. Pulse
pressure in younger patients <62 years was twice as likely
to cause death compared to older patients (RR 1.24 vs.
RR 1.12) Taken together, this study implies that those
with lower systolic blood pressure possibly with impaired
cardiac systolic function and wide pulse pressure have an
increased risk of total mortality. Lack of reporting of an-
tihypertensive drug use is a major shortcoming in this and
other cohorts.
Finally, in the Dialysis Outcomes and Practice Pat-
terns Study (DOPPS) [36], substantial heterogeneity
in the prevalence of hypertension was found with the
United States having the highest prevalence. Among
16,720 hemodialysis patients followed up to 5 years, crude
1-year mortality rates were 6.6% in Japan, 15.6% in
Europe, and 21.7% in the United States. In both uni-
variate and multivariate models, a diagnosis of hyperten-
sion was associated with reduced mortality (RR 0.74, P <
0.0001 in multivariate model). In the first year of dialysis,
the survival advantage of a diagnosis of hypertension was
large (RR = 0.59) but failed to retain its protective effect
(RR = 0.92, P > 0.05) subsequently.
CHOICE OF ANTIHYPERTENSIVE DRUGS
Only a limited number of studies have examined the
influence of the use of antihypertensive drugs and future
cardiovascular or total mortality. In general, the use of
antihypertensive drugs has been shown to reduce total
mortality in observational cohort studies, as noted above
[9, 34]. In the largest analysis, only beta blockers emerged
as an antihypertensive drug class that prolonged survival
by 16% after adjusting for other confounding factors [34].
ACE inhibitors, on the other hand, were found to have
no benefit in improving survival [34].
Calcium channel blockers are the most widely pre-
scribed antihypertensive drug class in patients with
ESRD for the treatment of hypertension. Kestenbaum
et al [37] analyzed the relationship of calcium channel
blockers use in prospective cohort of 4065 patients in
United States Renal Data System Morbidity and Mor-
tality Wave II and cardiovascular mortality [37]. Clinical
data, including medication information, were collected
60 days after the start of dialysis. Of the 3716 evaluable
patients, 51% were prescribed a calcium channel blocker.
The use of calcium channel blocker was associated with
a 21% lower risk of total mortality (RR 0.79, 95% CI
0.69 to 0.90) and a 26% lower risk of cardiovascular spe-
cific mortality (RR 0.74, 95% CI 0.60 to 0.91). In patients
with preexisting cardiovascular disease, calcium channel
blocker use was associated with a 23% and 22% lower
risk of total and cardiovascular mortality, respectively.
Efrati et al [38] reported their experience from Israel
in a retrospective cohort study of 60 patients who had
been treated with ACE inhibitors and 66 patients who
had not received the drug [38]. Although blood pres-
sure reduction was not significantly different between the
treated and untreated groups, mortality was reduced by
52% in the treated individuals (RR 0.48, 95% CI 0.25 to
0.91, P < 0.002). The relative risk reduction in individuals
<65 years of age was particularly notable (RR 0.21, 95%
CI 0.08 to 0.58, P = .0006).
From the above it is clear that no single class of drug is
advantageous. ACE inhibitors and beta blockers appear
attractive agents due to their independent cardiovascular
benefits.
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Table 2. Problems with cohort study analysis of existing studies
1 Blood pressure (risk factor) is not accurately measured which leads to “regression dilution bias”
2 Lack of consideration of blood pressure medications in statistical models; use of antihypertensive drugs is known to be protective, independent
of blood pressure reduction
3 Lack of consideration of cardiac function; high prevalence of cardiac dysfunction and underlying coronary artery disease with opposing effect
on blood pressure, complexly confound the effect of blood pressure on mortality
4 Too few patients or an inadequate follow-up; to see effect of hypertension as a risk factor in the general population, several years are generally
required; most dialysis studies are short-term
5 Systolic and diastolic blood pressures are considered in isolation; when not considered conjointly in the survival model, the effect of pulse
pressure is ignored which is known to predict outcomes in patients with and without kidney disease
6 Most hemodialysis studies are prevalent cohorts, not incident cohorts; some studies fail to report if they are incident or prevalent cohorts;
incident cohorts show an important effect of blood pressure as a risk factor for cardiovascular morbidity and mortality; excluding patients new
to dialysis may lead to biased estimates of attributable risk of hypertension
7 Other risk factors (e.g., diabetes, age, and smoking) may coexist and compete with hypertension in causing mortality; adjustment for these
variables, which are stronger risk factors for cardiovascular mortality, may dilute the effect of hypertension as a risk factor
8 Most studies report total mortality alone; cardiovascular morbidity such as strokes and nonfatal myocardial infarction are important events
that are often ignored in the analyses
9 Using blood pressure as a time-dependent covariate may dilute the relationship of the risk factor with events; for example, fall in blood
pressure with heart failure may not be attributed to preexisting hypertension if blood pressure is considered as a time-dependent covariate
Table 3. Suggestions for design of future studies to demonstrate a relationship between hypertension and cardiovascular morbidity and mortality
1 Accurate assessment of blood pressure is most important; most studies have not used standard methods for measurement of blood pressure; a
single interdialytic ambulatory blood pressure monitoring will provide information on blood pressure control as well as the pattern of control
2 Long follow-up and adequate numbers; biologically important covariates such as diabetes and smoking may need to be used as stratification
variables
3 Consideration of pharmacologic treatment of blood pressure since treatment itself provides an independent cardiovascular protection
4 Information on important covariates that lower blood pressure but increase cardiovascular mortality (e.g., congestive heart failure); baseline
echocardiogram would provide information not only on cardiac function but also cardiac structure
5 Consideration of systolic and diastolic blood pressure conjointly in the model that may offer information on pulse pressure
6 Mortality rate (a high mortality rate may not allow sufficient exposure to the risk factor to ascertain the importance of the risk factor, thus a
population with an expected survival of <12 months should be excluded); studying a lower risk population may uncover the deleterious effect
of hypertension
7 Total mortality, cardiovascular mortality, and nonfatal cardiovascular events should be measured
8 Studies should preferably be incident cohorts to avoid biased estimates
9 Measurement of nonconventional risk factors that may be important in causing atherosclerotic cardiovascular events and influencing blood
pressure (e.g., hemocysteine, human serum C-reactive protein, asymmetric dimethylarginine)
From a review of the existing literature, it is evident that
no single study has answered the question whether hyper-
tension is a cardiovascular risk factor in dialysis patients
and ascertained the magnitude of the risk. The shortcom-
ings of the current observational reports are summarized
in Table 2.
RECOMMENDATIONS FOR FUTURE STUDIES
In assessing hypertension as a risk factor for future
cardiovascular events, several factors need to be consid-
ered [39] and are summarized in Table 3. In clinical re-
search, risk is often assessed using a prospective cohort
design. Cohort studies produce estimates in the form of
relative risk, odds ratios, or hazard ratios, comparing the
incidence of disease among persons who have the given
risk factor, with the risk among those who do not have the
given risk factor. To prove independence of the hyperten-
sion as a risk factor, known confounders require that ad-
justments be made. Since atherosclerotic cardiovascular
disease, diabetes mellitus, and smoking often coexist with
hypertension in patients on hemodialysis, and are perhaps
stronger cardiovascular risk factors that hypertension per
se, the independent contribution of hypertension in caus-
ing cardiovascular morbidity and mortality has been dif-
ficult to demonstrate. Notably, the use of incident cohorts
with adequate follow-up of hypertensive patients with re-
nal failure who subsequently became normotensive, has
convincingly demonstrated, that hypertension is a risk
factor for total mortality [15]. These incident cohorts re-
cruited healthier patients with lower mortality rate. The
critical threshold for mortality appears to be about 10%
per year. If the mortality exceeds this threshold, expres-
sion of hypertension as a risk factor is confounded by
preexisting disease that contributes to high mortality, in-
dependent of hypertension.
Renal failure is a state of accelerated vascular aging.
Therefore, comparisons of patients on hemodialysis to
older individuals in the population appear appropriate.
In this context, pulse pressure and systolic blood pressure
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are found to be important for predicting cardiovascular
mortality in older hypertensive subjects in the general
population [40, 41]. Recent studies from Japan [23], as
well as from the United States Renal Data System cohort
[34], demonstrate the opposing influences of systolic and
diastolic blood pressure on total mortality. Furthermore,
studies from Okinawa, Japan, have reported a similar as-
sociation with myocardial infarctions and strokes [23].
Future studies examining the influence of blood pressure
on survival would need to consider the influence of sys-
tolic and diastolic blood pressures simultaneously in the
Cox proportional hazards model.
A large population attributable risk requires that the
risk factor be present in a large number of patients, and
the strength of the association be high. Hypertension, for
example, is highly prevalent and increases the risk for car-
diovascular events by a factor of 1.6 to 4.1 in women and
1.1 to 2.2 in men [42]. Therefore, it may account for a large
proportion of the cases of cardiovascular events in the
population. Among patients on hemodialysis nearly 85%
have hypertension and even a small risk ratio may ac-
count for a large population attributable risk among these
patients. Thus, finding even a slight elevation in risk with
hypertension is of enormous public health significance.
Large variations in blood pressure reduce the practical
value of this measure as a risk estimate for future mortal-
ity. The coefficient of variation should be low; this would
indicate good reproducibility. Accurate assessment of hy-
pertension in hemodialysis patients is difficult [43], and
measurement of blood pressure needs to be standard-
ized [44]. Most cohort studies have not taken standard-
ized blood pressure measurements and may have missed
the association between hypertension and cardiovascular
mortality, which may have otherwise been apparent. One
study that used ambulatory blood pressure monitoring to
predict outcomes was extremely successful in uncovering
such an effect with a limited number of patients [31]
Use of antihypertensive drugs confers an indepen-
dent protective effect on age-adjusted total mortality in
hemodialysis patients [9, 34]. Optimizing the dose, num-
ber, and timing of drug therapy may improve hyperten-
sion control.
In cohort studies beta blockers have been associated
with the reduction in total mortality of about 16% [34].
The use of ACE inhibitors and angiotensin receptor
blockers would also need to be tested for the efficacy
and safety in this population. Nonpharmacologic mea-
sures such as sodium restriction and limiting interdialytic
weight gain are important in achieving blood pressure
control. Intradialytic weight gain of >4.8% is associated
with increase in total mortality in long-term hemodialysis
patients [34]. Long-duration dialysis and nocturnal dial-
ysis are associated with better blood pressure control—
the mechanism of blood pressure reduction, regression
of LVH, and the durability of the response need to be
tested. Whether volume response hypertension has a dif-
ferent outcome than volume unresponsive hypertension
will need to be tested in future trials. Whether outcomes
of patients treated with volume control or more frequent
dialysis is different from those treated with pharmaco-
logic therapies is also unclear.
The optimal blood pressure goal in dialysis is unknown.
The safety and efficacy of goals of blood pressure, gener-
ally used in the population with essential hypertension or
with diabetes mellitus, needs to be tested in prospective
randomized trials. These goals may be confounded by the
presence of severe cardiovascular disease characterized
by vascular and ventricular stiffness. In such patients, goal
blood pressure may be higher to allow adequate perfusion
during dialysis. In this respect, the hemodialysis popula-
tion is unique—control of blood pressure may be associ-
ated with greater incidence of intradialytic hypotension,
cramps, dizziness, and intolerance to dialysis. Thus, future
trials would need assessment of quality-of-life in order to
make informed decisions on the use of antihypertensive
therapy in this population. Although in the elderly pop-
ulation, low diastolic blood pressure is associated with
increased cardiovascular events, it is reassuring that treat-
ment of isolated systolic hypertension in the elderly does
not increase the risk of cardiovascular morbidity or mor-
tality [45].
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